Skip to content

WellCareChina

Independent medical information for international patients

Menu

What advanced treatment technology is available in China

For some technologies China publishes a national licence list. For others it does not. This page separates the officially licensed from the merely reported — and shows how many clinical trials are recruiting in China right now.

Data as of 2025-12-08 (Class-A allocations) / 2026-06 (Hainan Boao Lecheng) / 2026-09-25 (trials query) · 21 sources · 6 items recorded as missing

Licensed proton & heavy-ion centres (Class A)

Configuration licences granted, by batch (hospitals)

Configuration licences granted, by batch (hospitals)Configuration licences granted — 2023 batch: 21; Configuration licences granted — 2024 first round: 5; Configuration licences granted — 2024 second round: 11; Configuration licences granted — 2025 batch: 5Configuration licences granted — 2023 batch21Configuration licences granted — 2024 first round5Configuration licences granted — 2024 second round11Configuration licences granted — 2025 batch5
Metric Value Year or as-of Caliber Level Source
Class A vs Class B equipment split — 2018 (国卫规划发〔2018〕12号) Class A (proton/heavy-ion, high-end radiotherapy) is configured and licensed by the National Health Commission; Class B by provincial health commissions. This determines whether a national list exists at all. Level A https://zwfw.nhc.gov.cn/bsp/jldxyysb/
2023 catalogue — Class A items — 2023-03-03 (国卫财务发〔2023〕7号) Class A: proton/heavy-ion radiotherapy systems; high-end radiotherapy equipment (MR-guided radiotherapy; X-ray stereotactic radiosurgery incl. CyberKnife); other first-time single units ≥ RMB 50 million. Level A https://www.nhc.gov.cn/bgt/c100258/202307/c4586946134f49bf8d9f36275aa6f6c0/files/1733795773553_95623.pdf
2023 catalogue — Class B items — 2023-03-03 Class B (provincial): PET/MR, PET/CT, laparoscopic surgical systems (surgical robots), conventional radiotherapy equipment (linacs, TOMO, GammaKnife), units RMB 30–50 million. No national installation list exists for these. Level A https://www.nhc.gov.cn/bgt/c100258/202307/c4586946134f49bf8d9f36275aa6f6c0/files/1733795773553_95623.pdf
2018 → 2023 classification change (TOMO moved to Class B) — 2018-03-29 → 2023-03-03 Under the 2018 catalogue TOMO and CyberKnife-style systems were Class A; the 2023 catalogue moved TOMO into Class B (provincial management) and narrowed Class A high-end radiotherapy to MR-guided + CyberKnife. Level A https://nirp.chinacdc.cn/fsaqssjb/fswsfgbzsjb/fgsjb/gfxwjsjb/202502/W020250219525324468989.pdf
Configuration licences granted — 2023 batch 21 published 2024-02-08 National Health Commission notice 国卫通〔2024〕1号 — licence granted, not installation Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Configuration licences granted — 2024 first round 5 published 2024-09-13 National Health Commission notice 国卫通〔2024〕13号 Level A https://www.nhc.gov.cn/caiwusi/c100043/202409/6842539e7ac64934b376e3166d1bf4e0.shtml
Configuration licences granted — 2024 second round 11 published 2025-03-17 NHC notice as reported by the Hebei provincial health commission (the NHC page itself was not retrievable by the research round) Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Configuration licences granted — 2025 batch 5 published 2025-12-08 National Health Commission notice (approved at the 10th directors' meeting of 2025) Level A https://www.nhc.gov.cn/caiwusi/c100043/202512/fd1e748e0c764c1ba145d01087948ee5.shtml
Cumulative configuration licences (proton / heavy-ion) 42 as of 2025-12-08 Sum of the four batches (21+5+11+5). Reported by the NMPA-supervised media as a cross-check of the arithmetic; the authoritative basis is the four official batch notices. Level B https://m.cnpharm.com/c/2025-12-10/1086443.shtml
Show all 51 rows
Metric Value Year or as-of Caliber Level Source
Beijing Tiantan Hospital, Capital Medical University Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Shanxi Provincial Cancer Hospital Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Peking University Cancer Hospital Inner Mongolia Hospital Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Shengjing Hospital of China Medical University Single-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
First Hospital of Jilin University Heavy-ion radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Harbin Medical University Cancer Hospital Single-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Shanghai Chest Hospital Single-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Fujian Provincial Cancer Hospital Heavy-ion radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Jiangxi Provincial Cancer Hospital Single-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Shandong First Medical University Affiliated Cancer Hospital Heavy-ion radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Henan Provincial Cancer Hospital Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Renmin Hospital of Wuhan University Heavy-ion radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Hunan Provincial Cancer Hospital Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Guangxi Zhuang Autonomous Region Cancer Hospital Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Hainan Provincial Cancer Hospital Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Chongqing Quanyu Cancer Hospital Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
West China Hospital, Sichuan University (Sichuan International Hospital) Heavy-ion radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Affiliated Hospital of Guizhou Medical University Heavy-ion radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
First Affiliated Hospital of Xi'an Jiaotong University Heavy-ion radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
First Hospital of Lanzhou University Multi-room proton radiotherapy system 2023 — Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0.shtml
Jinshazhou Hospital of Guangzhou University of Chinese Medicine Multi-room proton radiotherapy system 2024 first round — Level A https://www.nhc.gov.cn/caiwusi/c100043/202409/6842539e7ac64934b376e3166d1bf4e0.shtml
Zibo Wanjie Cancer Hospital Multi-room proton radiotherapy system 2024 first round — Level A https://www.nhc.gov.cn/caiwusi/c100043/202409/6842539e7ac64934b376e3166d1bf4e0.shtml
Guangzhou Taihe Cancer Hospital Multi-room proton radiotherapy system 2024 first round — Level A https://www.nhc.gov.cn/caiwusi/c100043/202409/6842539e7ac64934b376e3166d1bf4e0.shtml
Nanjing BenQ Hospital Single-room proton radiotherapy system 2024 first round — Level A https://www.nhc.gov.cn/caiwusi/c100043/202409/6842539e7ac64934b376e3166d1bf4e0.shtml
Anhui Wanbei Coal-Electricity Group General Hospital Single-room proton radiotherapy system 2024 first round — Level A https://www.nhc.gov.cn/caiwusi/c100043/202409/6842539e7ac64934b376e3166d1bf4e0.shtml
Peking Union Medical College Hospital Heavy-ion radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Shijiazhuang Edison Cancer Hospital Heavy-ion radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
First Affiliated Hospital of Soochow University Heavy-ion radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Union Hospital affiliated to Fujian Medical University Heavy-ion radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Jiangsu Provincial People's Hospital Multi-room proton radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
First Affiliated Hospital of Wenzhou Medical University Multi-room proton radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Sun Yat-sen University Cancer Center Multi-room proton radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Yunnan Provincial Cancer Hospital Multi-room proton radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Renji Hospital, Shanghai Jiao Tong University School of Medicine Single-room proton radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Qingdao University Affiliated Hospital Single-room proton radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Nanfang Hospital, Southern Medical University Single-room proton radiotherapy system 2024 second round — Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
Xuzhou Central Hospital Heavy-ion radiotherapy system 2025 — Level A https://www.nhc.gov.cn/caiwusi/c100043/202512/fd1e748e0c764c1ba145d01087948ee5.shtml
Huizhou Municipal Central Hospital Heavy-ion radiotherapy system 2025 — Level A https://www.nhc.gov.cn/caiwusi/c100043/202512/fd1e748e0c764c1ba145d01087948ee5.shtml
Changchun Cancer Hospital Single-room proton radiotherapy system 2025 — Level A https://www.nhc.gov.cn/caiwusi/c100043/202512/fd1e748e0c764c1ba145d01087948ee5.shtml
Heyou Hospital Heavy-ion radiotherapy system 2025 — Level A https://www.nhc.gov.cn/caiwusi/c100043/202512/fd1e748e0c764c1ba145d01087948ee5.shtml
Xi'an International Medical Center Hospital Heavy-ion radiotherapy system 2025 — Level A https://www.nhc.gov.cn/caiwusi/c100043/202512/fd1e748e0c764c1ba145d01087948ee5.shtml

High-end radiotherapy (Class A)

High-end radiotherapy licences granted, by batch (hospitals)

High-end radiotherapy licences granted, by batch (hospitals)High-end radiotherapy (Class A) licences — 2023: 17; High-end radiotherapy (Class A) licences — 2024 second round: 28; High-end radiotherapy (Class A) licences — 2025: 9High-end radiotherapy (Class A) licences — 202317High-end radiotherapy (Class A) licences — 2024 second round28High-end radiotherapy (Class A) licences — 20259
Metric Value Year or as-of Caliber Level Source
High-end radiotherapy (Class A) licences — 2023 17 published 2024-02-08 MR-guided radiotherapy and X-ray stereotactic radiosurgery (incl. CyberKnife) Level A https://www.nhc.gov.cn/wjw/c100175/202402/885cf828abb04dcb8949e1af69a250d0/files/1733224073243_74491.pdf
High-end radiotherapy (Class A) licences — 2024 second round 28 published 2025-03-17 Same two device families; the 2024 first-round list was not obtained, so no cumulative total is published Level A https://wsjkw.hebei.gov.cn/xwfb/410228.jhtml
High-end radiotherapy (Class A) licences — 2025 9 published 2025-12-08 X-ray stereotactic radiosurgery (incl. CyberKnife) 7 hospitals; MR-guided radiotherapy 2 hospitals. No cumulative figure is published: the 2024 first-round list was not obtained, and a hospital can appear in more than one batch. Level A https://www.nhc.gov.cn/caiwusi/c100043/202512/fd1e748e0c764c1ba145d01087948ee5.shtml

Hainan Boao Lecheng pilot zone

Innovative drugs and devices introduced (cumulative)

Innovative drugs and devices introduced (cumulative)Innovative drugs/devices introduced (cumulative, incl. special foods): 560+; Innovative drugs/devices and special foods (cumulative): 580+; Products accelerated to market via the real-world-evidence channel: 26Innovative drugs/devices introduced (cumulative, incl. special foods)560+Innovative drugs/devices and special foods (cumulative)580+Products accelerated to market via the real-world-evidence channel26
Metric Value Year or as-of Caliber Level Source
Innovative drugs/devices introduced (cumulative, incl. special foods) 560+ as of 2026-05-13 Hainan provincial government figure; the count rolls monthly and the scope includes special foods Level A https://www.hainan.gov.cn/hainan/wjjg/202605/a1819ce7190a4548b0b48783cf6a7204.shtml
Innovative drugs/devices and special foods (cumulative) 580+ as of 2026-06-07 Official-media figure (level B); the count includes special foods and is dated 2026-06-07. Level B https://hain.chinadaily.com.cn/a/202606/07/WS6a250a23a310942cc49b058a.html
Products accelerated to market via the real-world-evidence channel 26 as of 2026-06-07 Same official-media source Level B https://hain.chinadaily.com.cn/a/202606/07/WS6a250a23a310942cc49b058a.html
Patient uses of licensed products, 2026 Q1 30,000+ 2026 Q1 Hainan provincial government figure; +69.85% year on year Level A https://www.hainan.gov.cn/hainan/wjjg/202605/a1819ce7190a4548b0b48783cf6a7204.shtml

Recruiting trials with sites in China

Recruiting studies with a site in China (2026-09-25)

Recruiting studies with a site in China (2026-09-25)Colorectal cancer: 458; Breast cancer: 654; Lung cancer: 931; Liver cancer: 354; Cervical cancer: 659; Gastric cancer: 331; Prostate cancer: 191; Thyroid cancer: 77; Nasopharyngeal cancer: 152; Esophageal cancer: 234Colorectal cancer458Breast cancer654Lung cancer931Liver cancer354Cervical cancer659Gastric cancer331Prostate cancer191Thyroid cancer77Nasopharyngeal cancer152Esophageal cancer234
Metric Value Year or as-of Caliber Level Source
Colorectal cancer 458 2026-09-25 ClinicalTrials.gov API v2, filter.overallStatus=RECRUITING + query.locn=China; global comparator 1,578 (29.0%). Recruiting-study count with a China site — not hospital capability, not efficacy evidence. Level A https://clinicaltrials.gov/api/v2/studies?query.cond=colorectal+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Breast cancer 654 2026-09-25 Same query pattern; global comparator 2,451 (26.7%) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=breast+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Lung cancer 931 2026-09-25 Same query pattern; global comparator 2,315 (40.2%). Removing query.locn=China returns the global figure — the parameter is mandatory. Level A https://clinicaltrials.gov/api/v2/studies?query.cond=lung+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Liver cancer 354 2026-09-25 Same query pattern; global comparator 885 (40.0%) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=liver+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Cervical cancer 659 2026-09-25 Same query pattern; global comparator 1,879 (35.1%) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=cervical+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Gastric cancer 331 2026-09-25 Same query pattern; global comparator 725 (45.7%) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=gastric+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Prostate cancer 191 2026-09-25 Same query pattern; global comparator 1,225 (15.6%) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=prostate+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Thyroid cancer 77 2026-09-25 Same query pattern; global comparator 214 (36.0%) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=thyroid+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Nasopharyngeal cancer 152 2026-09-25 Same query pattern; global comparator 192 (79.2% — highest share of the ten) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=nasopharyngeal+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId
Esophageal cancer 234 2026-09-25 Same query pattern; global comparator 547 (42.8%) Level A https://clinicaltrials.gov/api/v2/studies?query.cond=esophageal+cancer&filter.overallStatus=RECRUITING&query.locn=China&countTotal=true&pageSize=1&fields=NCTId

Sources

Show all 21 sources

What we cannot tell you

  1. A configuration licence is not an operating machine: "licensed" does not mean "installed", "open" or "accepting international patients".
  2. TOMO, GammaKnife and surgical robots are managed at provincial level, so no national official installation list exists. We record this as missing rather than quoting a national number.
  3. CAR-T: no official hospital list or treated-patient count exists; conflicting third-party figures are not used anywhere on this site.
  4. Trial counts are recruiting studies with at least one site in China (ClinicalTrials.gov API v2, queried 2026-09-25 with query.locn=China). They are not a measure of hospital capability or of treatment effectiveness.
  5. The 42 licences are compiled from four official batch notices; no single official document lists them together.
  6. National list of TOMO installations — TOMO became a Class B (provincial) item in 2023, so no national government list exists. An industry-society survey figure is given on the treatment-volume page instead (level B).
  7. National list of GammaKnife installations — Class B item — provincial management, no national list.
  8. National list of surgical-robot installations — Class B item — provincial management, no national list.
  9. Number of hospitals able to provide CAR-T — No official list; third-party counts of approved products conflict (4/6/7) and are not cited on this site.
  10. Number of proton/heavy-ion centres already operating — Official notices grant configuration licences only. 'Operating' needs a second layer of evidence (provincial acceptance notices / hospital statements) which this round did not collect.
  11. ChiCTR recruiting counts by cancer type — ChiCTR has no public API (four candidate endpoints returned 404) and its search page sits behind an Alibaba Cloud WAF and shows no total count. Recorded as missing rather than estimated.